Kunxian capsules yields short-term clinical efficacy vs placebo for ankylosing spondylitis
Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trialTrials. 2016 Jul 22;17(1):337
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
80 patients with ankylosing spondylitis were randomized to receive a Chinese patent medicine, 0.6g Kunxian, or a placebo drug, 3 times daily for 12 weeks. The purpose of this study was to determine the efficacy of Kunxian, measured using the Assessment of SpondyloArthritis international Society (ASAS) 20 response rate. Other outcomes included ASAS 40, Bath Ankylosing Spondylitis Disease Activity I...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE